Want to see IT:FF full AI Analyst Report?
Top Page
Fine Foods & Pharmaceuticals N.T.M. SpA
(FF)
Select Model
Select Model
Rating:49Neutral
Price Target:
€7.00
▼(-19.54% Downside)
Action:Reiterated
Date:09/11/26
The score is held back primarily by weakening financial quality (TTM net loss, sharp margin compression, higher leverage, and thin/volatile free cash flow) and very bearish technical conditions (below all major moving averages with negative momentum). Valuation provides only partial support, with a moderate dividend yield but a mid-to-high P/E given current profitability pressures.
Positive Factors
Strong Revenue Growth
Revenue growth of 24.6% indicates meaningful demand across the company’s pharmaceutical manufacturing and commercial activities. If sustained, this expanding top line can improve operating scale, support customer relationships, and provide a base for rebuilding profitability over coming quarters.
Negative Factors
Profitability Compression
The shift to a TTM net loss, together with the sharp gross-margin decline, signals materially weaker earnings quality and reduced pricing or cost absorption. Persistent compression would limit reinvestment, weaken returns, and make revenue growth less valuable to shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Revenue growth of 24.6% indicates meaningful demand across the company’s pharmaceutical manufacturing and commercial activities. If sustained, this expanding top line can improve operating scale, support customer relationships, and provide a base for rebuilding profitability over coming quarters.
Read all positive factors
Fine Foods & Pharmaceuticals N.T.M. SpA (FF) vs. iShares MSCI Italy ETF (EWI)
Market Cap
€175.99M
Dividend Yield2.2%
Average Volume (3M)31.99K
Price to Earnings (P/E)―
Beta (1Y)0.47
Revenue Growth-0.61%
EPS Growth-110.39%
CountryIT
Employees834
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)-0.07
Shares Outstanding22,060,125
10 Day Avg. Volume47,356
30 Day Avg. Volume31,987
Financial Highlights & Ratios
PEG Ratio0.96
Price to Book (P/B)1.82
Price to Sales (P/S)0.97
P/FCF Ratio-85.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€10.90Price Target Upside25.29% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.42
Revenue Forecast (FY)€260.92M
Fine Foods & Pharmaceuticals N.T.M. SpA Business Overview & Revenue Model
Company Description
Fine Foods & Pharmaceuticals N.T.M. S.p.A. functions as a contract development and manufacturing organization (CDMO), specializing in the creation of various oral solid forms for the pharmaceutical and nutraceutical sectors. Its pharmaceutical off...
How the Company Makes Money
FF generates revenue primarily by providing manufacturing and related services to third-party customers and by selling/distributing pharmaceutical and nutraceutical products through its commercial operations. Key revenue streams therefore typicall...
Fine Foods & Pharmaceuticals N.T.M. SpA Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
52
Neutral
Cash Flow
47
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 249.02M | 252.06M | 243.75M | 251.81M | 206.85M | 194.42M |
| Gross Profit | 29.10M | 35.42M | 80.13M | 68.56M | 53.63M | 55.89M |
| EBITDA | 28.74M | 33.31M | 30.90M | 19.29M | 3.64M | 9.86M |
| Net Income | -1.04M | 10.10M | 8.16M | -3.52M | -9.50M | -1.43M |
Balance Sheet | ||||||
| Total Assets | 316.90M | 280.02M | 242.59M | 241.56M | 299.82M | 302.81M |
| Cash, Cash Equivalents and Short-Term Investments | 36.34M | 38.88M | 19.21M | 19.15M | 76.74M | 95.09M |
| Total Debt | 133.82M | 86.78M | 54.53M | 66.39M | 120.36M | 110.76M |
| Total Liabilities | 200.87M | 145.82M | 110.53M | 114.61M | 166.53M | 155.59M |
| Stockholders Equity | 116.03M | 134.21M | 132.06M | 126.95M | 133.29M | 147.22M |
Cash Flow | ||||||
| Free Cash Flow | 2.75M | -2.87M | 11.12M | -329.75K | -12.30M | -21.75M |
| Operating Cash Flow | 32.42M | 31.76M | 45.85M | 18.54M | 3.69M | -5.83M |
| Investing Cash Flow | -72.02M | -35.85M | -31.56M | 45.89M | -15.31M | -36.35M |
| Financing Cash Flow | 39.04M | 23.76M | -14.08M | -55.66M | 4.74M | 55.95M |
Fine Foods & Pharmaceuticals N.T.M. SpA Technical Analysis
Negative
8.70
Price Trends
8.12
Negative
8.44
Negative
9.01
Negative
Market Momentum
-0.35
Negative
35.03
Neutral
60.39
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:FF, the sentiment is Negative. The current price of 8.7 is above the 20-day moving average (MA) of 7.61, above the 50-day MA of 8.12, and below the 200-day MA of 9.01, indicating a bearish trend. The MACD of -0.35 indicates Negative momentum. The RSI at 35.03 is Neutral, neither overbought nor oversold. The STOCH value of 60.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IT:FF.
Fine Foods & Pharmaceuticals N.T.M. SpA Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | €788.54M | 2.28 | ― | ― | 81.20% | 104.98% | |
66 Neutral | €113.30M | 14.19 | 7.29% | 3.62% | 1.44% | -20.62% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
49 Neutral | €175.99M | -110.84 | ― | 2.20% | -0.61% | -110.39% |
* Consumer Defensive Sector Average
IT:FF
Fine Foods & Pharmaceuticals N.T.M. SpA
7.18
-1.51
-17.37%
IT:VLS
Valsoia SpA
10.60
-0.52
-4.70%
IT:ENV
Enervit S.p.A.
5.40
1.39
34.70%
IT:IWB
Italian Wine Brands S.p.A.
16.68
-4.87
-22.58%
IT:ERFO
Laboratorio Farmaceutico Erfo SpA
1.08
-0.41
-27.52%
IT:NWL
NewPrinces S.p.A.
17.83
-4.87
-21.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.